Market Overview

UPDATE: Citigroup Upgrades Biogen Idec to Buy on Strong Fundamentals

Share:
Related BIIB
Baird Still Isn't Buying Biogen
15 Biggest Mid-Day Gainers For Thursday
Biotech Forum Daily Digest: Will Biotech Finally Break Out? All Eyes On Gilead, Spotlight On Seres Therapeutics (Seeking Alpha)

Citigroup upgraded Biogen Idec (NASDAQ: BIIB) from Neutral to Buy and raised the price target from $160.00 to $187.00.

Citigroup commented, "We are upgrading Biogen to Buy as we simply do not see a better entry point anytime soon. We have been on the sidelines hoping to find material weakness, but alas, the fundamentals are too strong and recent PEG-Avonex positive ph 3 data and Tysabri acq from Elan should lead to sustainable upside relative to expectations. We expect that Biogen will come to dominate the MS market in the same way that Gilead dominates HIV and this should lead to tremendous operating synergy and margin expansion. Along with a deep mid-stage pipeline, Biogen should provide sustainable long-term revs/EPS growth."

Biogen Idec closed at $161.75 on Thursday.

Latest Ratings for BIIB

DateFirmActionFromTo
Jul 2016Morgan StanleyMaintainsOverweight
Jun 2016BernsteinInitiates Coverage onOutperform
Jun 2016CitigroupMaintainsBuy

View More Analyst Ratings for BIIB
View the Latest Analyst Ratings

Posted-In: CitigroupAnalyst Color Upgrades Analyst Ratings

 

Related Articles (BIIB)

View Comments and Join the Discussion!